Singulex to Develop Assays to Assess Efficacy of Cancer Therapeutics
News Jul 30, 2008
Singulex Inc. has announced that it secured the second phase of its Fast Track Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The company will use the funds to develop biomarker assays that will be useful in determining whether a potential cancer therapeutic is effective.
Because the levels of specific proteins vary depending on disease state, biomarkers, or proteins associated with a disease, can be measured to determine whether a disease is progressing.
In addition, by measuring changes to disease-associated biomarkers following treatment with a specific drug, pharmaceutical developers can assess whether a drug candidate demonstrates efficacy.
However, despite the identification and validation of cancer- associated biomarkers, technologies have not existed that allow detection sensitively enough to see the subtle changes that enable drug developers or clinicians to use biomarkers to assist in the development of medicines or to make clinical decisions.
The NCI SBIR contract will continue to support Singulex's assay development in collaboration with researchers at Washington University and Sigma Aldrich. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261200700047C.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE